documented protocols
Follistatin-344: what is documented about dosing
The trials state what they delivered. One delivered a gene and the other a different molecule into a single named muscle, and neither describes an amount of the protein that is sold.
- Primary sources Registry records and papers are read at the source, not through summaries. Read the methodology
- Every claim graded Each claim about what a compound does carries an evidence tier and a numbered citation. How grades derive
- Sells nothing No cart, no price, and no product page anywhere on this site. Conflict disclosure
- Corrections logged Errors are fixed and recorded in a permanent public log, never edited away. Corrections log
What follows is what the registered studies administered, reported as that and nothing else.
Not medical advice
This page reports what has been documented about a compound. It is not medical advice, not a diagnosis, not a dosing protocol, and not a recommendation to obtain or use anything described here. Talk to a licensed clinician about anything concerning your health. Read the full disclaimer.
Reviewed against editorial standards Updated
What this page reports, and what it does not
We report what has been documented. We do not prescribe what should be done.
Nothing here is a dosing recommendation. Statements about dosing reflect community and research reports only.
No trial established an amount of Follistatin-344 for a person. Most of the rows below record what a published study gave to its animals or its cells, in the model that study built, with the species and the route named on the line. One row records that other figures circulate in community write-ups, and that this site does not republish them. Nothing here is a protocol, nothing here is scaled for a person, and this site publishes no preparation steps, no administration technique and no equipment. The reasoning is in the editorial policy.
Commonly cited protocols (extrapolated, not validated)
| Study | What was given | Frequency | Duration | Notes |
|---|---|---|---|---|
| Gene transfer trials | A quantity of viral vector, not a quantity of protein | Single administration to muscle | One-off, with the muscle then expressing the protein | Becker and Duchenne studies, 15 and 3 participants. Not comparable to a protein injection |
| ACE-083 Phase 2 | 240 mg per muscle in the published reports | Injected bilaterally as described in each protocol | Six months to the primary endpoint | A different molecule, designed to act in one named muscle rather than to circulate. Both trials terminated |
| Injected follistatin protein | Nothing documented | Nothing documented | Nothing documented | No registered or published study exists of the product that is sold |
Commonly cited protocols (extrapolated, not validated) circulate for this compound in microgram amounts by injection. They did not come from a study, because no study of an injected follistatin protein in a person exists.
Neither trial figure converts. A quantity of viral vector is not a quantity of protein and the two are not related by any published conversion. The ACE-083 figure belongs to a different molecule designed to stay where it is placed, which is the opposite of what a systemic product is meant to do.
Nothing here is a dosing recommendation. Statements about dosing reflect community and research reports only.
Our takeTwo sets of real numbers exist and neither describes the product being sold. There is no documented amount for an injected follistatin protein in a person.,Talk to a licensed clinician about anything concerning your health.
Main routes people compare
Injection of the protein
The route the product is sold for. No published study has measured what an injected follistatin protein does in a person.
Gene transfer to muscle
The route used in every human trial carrying this compound's name. A virus or a plasmid delivers the gene and the muscle produces the protein in place, which is a different intervention rather than a different route to the same one.
A locally acting fusion protein
The route used in the ACE-083 programme, which injected a different molecule into one named muscle at a time so that it would act there rather than circulate.
What is said about cycle length and timing
No cycle length appears in the published record for an injected follistatin protein. The ACE-083 trials ran to a six-month primary endpoint with a further six-month extension, and the gene transfer studies were single administrations.
Talk to a licensed clinician about anything concerning your health.
What has been measured about safety
A reader weighing what other people report giving usually wants the other half of the record next. What has been measured about Follistatin-344, and what has never been studied reports what has actually been measured, in what system and over what period, and the questions no published study has put.
Frequently asked questions
Is there an established dose for injected follistatin?
No. No registered or published study has given an injected follistatin protein to a person, so no amount has been established.
Can the gene therapy figures be converted?
No. Those trials delivered a quantity of viral vector so that muscle would produce the protein in place. A vector quantity and a protein quantity are not related by any published conversion.
What about the 240 mg used in the ACE-083 trials?
That belongs to a different molecule, given so that it acts in one named muscle. Both Phase 2 trials using it were terminated.
References
- Nationwide Children's Hospital. Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy. Phase 1, 15 participants, completed, no posted results. Intervention rAAV1.CMV.huFollistatin344, typed BIOLOGICAL in the registry record. Read through the v2 API on 23 August 2026. ClinicalTrials.gov. 2012. NCT01519349
- Mendell JR. Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344. Phase 1/2, 3 participants, completed, results posted. Duchenne muscular dystrophy. ClinicalTrials.gov. 2015. NCT02354781
- Mendell JR, Sahenk Z, Malik V, Gomez AM, Flanigan KM, Lowes LP, Alfano LN, Berry K, Meadows E, Lewis S, Braun L, Shontz K, Rouhana M, Clark KR, Rosales XQ, Al-Zaidy S, Govoni A, Rodino-Klapac LR, Hogan MJ, Kaspar BK. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther. 2015. PMID 25322757 Identified from PubMed metadata; the full text was not read for this page.
- Glasser CE, Gartner MR, Wilson D, Miller B, Sherman ML, Attie KM. Locally acting ACE-083 increases muscle volume in healthy volunteers. Muscle Nerve. 2018. PMID 29486514 DOI 10.1002/mus.26113 Phase 1 in 58 healthy postmenopausal women, 42 on drug and 16 on placebo. Maximum mean muscle volume increases of 14.5 per cent and 8.9 per cent, with no significant changes in mean muscle strength, and no serious adverse events or dose-limiting toxicities. Read as an abstract.
- Acceleron Pharma, Inc. Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy. Phase 2, 95 participants, terminated, results posted. The registry's whyStopped field reads: Study was discontinued as it did not achieve functional secondary endpoints. ClinicalTrials.gov. 2016. NCT02927080
- Acceleron Pharma, Inc. Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease. Phase 2, 63 participants, terminated, results posted. The registry's whyStopped field records that investigation was discontinued as it did not achieve functional secondary endpoints in the parent trial. ClinicalTrials.gov. 2017. NCT03124459
- Acceleron Pharma, Inc. Extension Study to Evaluate the Long-Term Effects of ACE-083. Phase 2, 62 participants, terminated, results posted. The registry records that investigation was discontinued because functional secondary endpoints were not achieved in the parent trials. ClinicalTrials.gov. 2019. NCT03943290
- Patel K. Follistatin. Int J Biochem Cell Biol. 1998. PMID 9785474 A review of the protein and its splice forms, including the 344 and 315 residue variants.
- Minicircle. Phase I: Safety and Efficacy of an Injectable Follistatin Plasmid. 43 participants, completed, no posted results. Intervention typed GENETIC in the registry record. This site states what the registry records and nothing about the organisation. ClinicalTrials.gov. 2024. NCT06411366
- Minicircle. Follistatin and klotho gene therapy in healthy adults. Early Phase 1, 30 participants, recruiting as of 23 August 2026. ClinicalTrials.gov. 2026. NCT07285629
- Rodino-Klapac LR, Haidet AM, Kota J, Handy C, Kaspar BK, Mendell JR. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve. 2009. PMID 19208403 Identified from PubMed metadata; the full text was not read for this page.
- Reichel C, Gmeiner G, Thevis M. Detection of black market follistatin 344. Drug Test Anal. 2019. PMID 31758732 DOI 10.1002/dta.2741 Seventeen black-market products were analysed. Nine contained follistatin; in some of the others growth-promoting peptides including MGF and GHRP-2 were found. All nine positive samples contained His-tagged FS344 and a high degree of its oligomers. Read as an abstract, which states these figures explicitly.